- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Stribild, Single-Tablet HIV Regimen, Demonstrates Long-Term Viral Suppression
Treatment shows sustained efficacy over 3 years (October 16)
Positive long-term (144-week) efficacy and safety results have been reported from two pivotal phase III studies of the once-daily single-tablet regimen Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg; Gilead Sciences) in treatment-naïve patients with human immunodeficiency virus-1 (HIV-1) infection.
The new data show that after 3 years of treatment, the efficacy of Stribild was comparable with that of two standard-of-care HIV regimens: Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg; Bristol-Myers Squibb/Gilead) in one study, and a protease inhibitor-based regimen of ritonavir-boosted atazanavir plus Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg; Gilead) in the other study.
The new findings are being presented this week at the 14th European AIDS Clinical Society Conference (EACS) in Brussels, Belgium.
In the first study, after 144 weeks of treatment, 80% of Stribild-treated patients (n = 279/348) achieved HIV RNA (viral loads) of less than 50 copies/mL compared with 75% of patients receiving Atripla (n = 265/352).
Similarly, in the second study, 78% of Stribild-treated patients (n = 274/353) compared with 75% of patients taking a protease inhibitor-based regimen of ritonavir-boosted atazanavir plus Truvada (n = 265/355) achieved HIV RNA of less than 50 copies/mL.
Stribild is indicated in the U.S. as a complete regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naïve. Stribild does not cure HIV-1 infection.
Source: Gilead Sciences; October 16, 2013.